Aurubis AG buy Traumtanz
Start price
05.11.24
/
50%
€80.40
Target price
05.11.25
€82.00
Performance (%)
1.99%
End price
08.11.24
€82.00
Summary
This prediction ended on 08.11.24 with a price of €82.00. With a performance of 1.99%, the BUY prediction by Traumtanz for Aurubis AG closed with a slight gain. Traumtanz has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Aurubis AG | -2.143% | -2.143% |
| iShares Core DAX® | -1.315% | -2.266% |
| iShares Nasdaq 100 | 0.272% | 1.449% |
| iShares Nikkei 225® | -2.496% | 1.560% |
| iShares S&P 500 | 0.504% | 1.340% |
According to Traumtanz what are the pros and cons of Aurubis AG for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
High dividend yield expected
positive Cash Flow expected
Good rating
Standard Investments for future growth
ROE higher than 10% per year
Normal challenges to pay loans and raise capital
Innovative
Differentiated customer and product portfolio
Growths faster than the competition
Sustainability is important
Stable Large shareholder and/or long term investor
Medium risks for its business
Small cyclical dependencies
Future proof or reliable business model
Revenue growth >5% per year expected
Valuable balance sheet
Capable Management
Good culture
Some uniques
Top 10 in its market
Well known brand
Cons
Comments by Traumtanz for this prediction
In the thread Aurubis AG diskutieren
In the thread Trading Aurubis AG
Stopped prediction by Traumtanz for Aurubis AG
Aurubis AG
Start price
Target price
Perf. (%)
€74.00
22.01.25
22.01.25
€85.00
22.01.26
22.01.26
-1.55%
28.01.25
28.01.25
Could be worthwhile Investment >10% per year
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
Aurubis AG
Start price
Target price
Perf. (%)
€83.20
06.12.24
06.12.24
€85.00
06.12.25
06.12.25
-11.06%
22.01.25
22.01.25
Could be worthwhile Investment >10% per year
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation